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Abstract
This article is one of ten reviews selected from the
Annual Update in Intensive Care and Emergency
Medicine 2019. Other selected articles can be found
online at https://www.biomedcentral.com/collections/
annualupdate2019. Further information about the
Annual Update in Intensive Care and Emergency
Medicine is available from http://www.springer.com/
series/8901.
Introduction: Why is this topic important?
Community-acquired pneumonia (CAP) is associated
with high morbidity and mortality worldwide [1]. Al-
though several different bacteria and respiratory viruses
can be responsible for CAP, Streptococcus pneumoniae
(pneumococcus) remains the most common causative
pathogen. A small proportion of CAP cases are caused
by Gram-negative bacteria, especially Pseudomonas aer-
uginosa, Klebsiella pneumoniae, Acinetobacter bauman-
nii and Stenotrophomona maltophilia [2, 3]. The main
problem concerning the treatment of Gram-negative
bacterial infections is their related antibiotic resistance,
reported as multidrug resistant (MDR = resistant to at
least one agent in three or more groups of antibiotics),
extensively drug resistant (XDR = resistant to at least
one agent in all but two or fewer groups of antibiotics)
and pan-drug resistant (PDR = resistant to all groups of
antibiotics) [4]. This makes the clinical management of
pneumonia caused by such pathogens a challenge for
physicians. Taking into account the clinical severity that
may be associated with CAP caused by Gram-negative
bacteria (respiratory failure, bacteremia, shock, acute re-
spiratory distress syndrome [ARDS]) the magnitude of
the global health problem is tremendous.
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We are currently living through an antibiotic resistance
crisis, mainly because antibiotics tend to lose their efficacy
over time due to the emergence and dissemination of resist-
ance among bacterial pathogens, principally caused by the
overuse and inappropriate use of antibiotics, as well as the
extensive use of antibiotics in agriculture and the food in-
dustry. The Global Point Prevalence Survey (Global-PPS),
an international network set up to measure antimicrobial
prescription and resistance in the hospital setting, recently
published its findings [5]. Pneumonia was the most com-
mon illness to receive antibiotic therapy worldwide, ac-
counting for 19% of patients treated. The most frequently
prescribed antibiotics for community-acquired infections
were penicillins with a β-lactamase inhibitor (29%); amoxi-
cillin with a β-lactamase inhibitor accounted for 16% and
piperacillin with a β-lactamase inhibitor accounted for 8%.
Third-generation cephalosporins were the second most
commonly prescribed antibiotics for community-acquired
infections (mainly ceftriaxone, 16%), followed by fluoroqui-
nolones (14%).
Antibiotic resistance is a natural phenomenon in bac-
teria that cannot be stopped; however various measures
can be taken in order to reduce the rate of its develop-
ment and devise more effective strategies to control its
spread [6].
Because CAP caused by MDR Gram-negative bacteria
is an important clinical concern, we review the main
findings concerning the epidemiology, diagnosis and
clinical impact of CAP.
CAP caused by Pseudomonas aeruginosa
The pathogen: Why is it difficult to treat?
P. aeruginosa is an opportunistic Gram-negative,
non-fermentative bacterium that inhabits the soil and
surfaces in aqueous environments. Its high intrinsic anti-
biotic resistance, broad metabolic versatility and adapt-
ability make it especially difficult to treat. Several studies
have shown that the physical characteristics (phenotype)
of P. aeruginosa isolates vary between those derived
from chronic infections, such as cystic fibrosis, and
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those from acute infections, such as pneumonia [7].
Common chromosomal mutations in the mucA gene
can convert a non-mucous phenotype into a mucous
phenotype. The adaptation of P. aeruginosa, which
includes complex physiological changes, confers a se-
lective advantage since it can better survive in differ-
ent habitats [8].
P. aeruginosa has intrinsic, adaptive and acquired
mechanisms of resistance, the main ones including the
presence of β-lactamases, alterations in membrane per-
meability due to the presence of ejection pumps, and
mutations of transmembrane porins. Furthermore, the
capacity to form biofilms (intricate, highly organized
bacterial communities, embedded in a matrix composed
of exopolysaccharides, DNA and proteins that is at-
tached to a surface and hinders antimicrobial action) fa-
vors the persistence of P. aeruginosa and makes it more
difficult to treat, due to the inherent protection that bio-
films provide [8] (Table 1).
A large number of intrinsic P. aeruginosa virulence
factors are required to establish infection [7]. Moreover,
the differential presence or expression of some of these
virulence factors may determine major inter-strain vari-
ability in virulence and thus potentially have a major im-
pact on disease severity and mortality [8].
In conclusion, the pathogenesis of P. aeruginosa CAP
is very complex, in addition to the broad antimicrobial
resistance that limits antibiotic therapy; the virulence of
P. aeruginosa is certainly a major driver of pneumonia
severity and outcome, as well as the different phenotypes
described. The capacity to form biofilms provides the
bacteria with a further possibility to escape the effects of
antibiotics, turning it into a superbug.
Prevalence: What is the prevalence?
The reported prevalence of CAP caused by P. aeruginosa
is controversial, largely due to data being limited to
single-center studies and because of differences in the
study populations [9] (Table 2). Recently, a multinational
point-prevalence study analyzed data from 3193 CAP
patients in 222 hospitals in 54 countries [10]. The study
showed a low prevalence of CAP caused by P. aerugi-
nosa (4.2%), which corresponded to only 11.3% of pa-
tients with culture-positive pneumonia. The prevalences
of antibiotic-resistant and MDR P. aeruginosa were also
low (2 and 1% respectively). Interestingly, the study re-
ported the prevalence of P. aeruginosa in CAP in differ-
ent continents: 3.8% in Europe, 4.3% in North America,
5.2% in Asia, 4.9% in South America, 5.5% in Africa and
3.1% in Oceania. The prevalence of antibiotic-resistant
P. aeruginosa in CAP was 1.6% in Europe, 2.5% in North
America, 2.2% in Asia, 3.0% in South America, and 3.9%
in Africa; there were no reported cases of P. aeruginosa
antibiotic resistance in Oceania. Finally, the prevalence
of MDR P. aeruginosa in CAP was 0.9% in Europe, 1.2%
in North America, 0.5% in Asia, 2% in South America,
and 2.3% in Africa; there were no cases of MDR P. aeru-
ginosa in Oceania.
Similarly, a Spanish study of clinical outcomes and risk
factors for CAP caused by MDR and non-MDR P. aerugi-
nosa reported a prevalence of MDR P. aeruginosa of 1.1%
in a prospective cohort study of 2023 culture-positive
CAP patients [11]. The authors also reported that P. aeru-
ginosa was an individual risk factor associated with mor-
tality in the study population.
A study by Ferrer et al. [12] of 664 severe CAP cases
requiring mechanical ventilation showed that 336 pa-
tients had a final microbiological diagnosis; P. aerugi-
nosa was reported in 7% (n = 25) of cases (4% in the
non-invasive mechanical ventilation group and 5% in the
invasive mechanical ventilation group).
P. aeruginosa risk factors
Antibiotic therapy for P. aeruginosa is totally different
from the standard antimicrobial therapy used to treat
common CAP pathogens. Current recommendations
Table 1 Main resistance mechanisms in Gram-negative
pathogens
Microorganism Mechanism
Pseudomonas aeruginosa Efflux pumps
Mutant topoisomerases
Modifying enzymes
AmpC/porin reduction combinations
Metallo-b-lactamases
Outer membrane permeability
Extended spectrum β-lactamases
Acinetobacter baumannii β-lactamases
Efflux pumps
Membrane permeability
Aminoglycoside-modifying enzymes
Alteration of target sites
Klebsiella pneumoniae Modifying enzyme
Efflux pumps
Mutant topoisomerases
Extended spectrum β-lactamases
Carbapenemases
Stenotrophomonas maltophilia β-lactamases (L1 and L2)
Multidrug efflux pumps
Antibiotic-modifying enzymes
Mutations of bacterial topoisomerase
and gyrase genes
Reduction in outer membrane
permeability
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provided by international guidelines stratify therapy on
the basis of Pseudomonas risk factors [1, 13].
Risk factors for P. aeruginosa include structural lung
disease (bronchiectasis, chronic obstructive pulmonary
disease [COPD]), nursing home residence, C-reactive
protein (CRP) < 12.35 mg/dL, prior use of oral steroids,
antibiotic therapy within the previous 90 days, and mal-
nutrition [1, 11]. Chronic P. aeruginosa colonization in
patients with bronchiectasis and COPD can be an im-
portant preliminary step to pneumonia. Non-cystic fi-
brosis bronchiectasis and COPD account for 2–55% and
for 20–46% of CAP cases, respectively. These two struc-
tural lung conditions facilitate chronic colonization by P.
aeruginosa, mainly due to failure to eradicate the bacter-
ium during acute infections. As mentioned earlier, P.
aeruginosa can transform from a non-mucous pheno-
type to a mucous phenotype which can then adapt to
the lung environment and grow as a biofilm.
Interestingly, a recent case-control study [14] identi-
fied risk factors for pneumonia due to P. aeruginosa sus-
ceptible to all routinely tested antipseudomonal
β-lactams (APBL-S) and resistant to at least one anti-
pseudomonal β-lactam (APBL-R). The authors identified
bronchiectasis, interstitial lung disease, prior airway
colonization with P. aeruginosa and recent exposure to
an antipseudomonal β-lactam as risk factors for APBL-S
P. aeruginosa in adults with acute bacterial pneumonia.
In the last few years, cases of P. aeruginosa infection
in previously healthy individuals have been reported; in
the majority, heavy exposure to aerosols of contaminated
water has been identified [15].
P. aeruginosa can establish polymicrobial interactions,
mainly with Staphylococcus aureus and Candida albicans
that may affect disease management. The relationship
between S. aureus and P. aeruginosa is competitive in na-
ture. The association of C. albicans with P. aeruginosa or
S. aureus enhances disease severity in several ways. In vivo
studies in rats have shown that pre-colonization of lung
tissue by C. albicans increases the rate of pneumonia
caused by P. aeruginosa. This microbial interaction should
be taken into account in patients with COPD or
non-cystic fibrosis bronchiectasis who are frequently colo-
nized with P. aeruginosa and S. aureus [16].
According to a recent study, prior antibiotic treatment
is a risk factor for P. aeruginosa, especially for MDR P.
aeruginosa [11]. It has been demonstrated that low levels
of antibiotics contribute to strain diversification in P.
aeruginosa; sub-inhibitory and sub-therapeutic antibiotic
concentrations induce alterations that effect changes in
gene expression, horizontal gene transfer and mutagen-
esis, which can promote and spread antibiotic resistance.
Given that P. aeruginosa CAP has been related to poor
clinical outcomes, largely because of inappropriate em-
piric antibiotic treatment, it is recommended to use em-
piric anti-pseudomonal cover in all cases of highly
suspected MDR P. aeruginosa CAP. Risk stratification
should take into account the local ecology (prevalence of
the pathogen in a specific area) and the patient’s risk fac-
tors, especially in cases of severe CAP that are associated
with higher mortality rates (20–50%) [1].
CAP caused by Acinetobacter baumanii
The pathogen: How important is A. baumanii in CAP?
A. baumannii is an aerobic Gram-negative coccobacillus.
In 2017, the World Health Organization (WHO) in-
cluded it in the list of “Priority Pathogens”, a group of
bacteria that poses the greatest threat to human health
and for which new antibiotics are urgently needed [17].
Table 2 Incidence and risk factors for Pseudomonas aeruginosa community-acquired pneumonia (CAP)
Study/year Population/Country Prevalence of P. aeruginosa Risk factors for P. aeruginosa CAP
Aliberti et al. 2013 [2] Prospective study of two cohorts
(Barcelona and Edinburgh) n = 1591
CAP patients
Barcelona: 6.5% (32 cases) of these 12
cases (38%) were MDR P. aeruginosa
Edinburgh: 1.6% (9 cases) of these 3
cases (30%) were MDR P. aeruginosa
Nursing home; hospitalization in the
previous 90 days; history of chronic
lung disease
Shindo et al. 2013 [51] Prospective study of CAP and HCAP
cases from Japan n = 1431
CAP 3.7% (33 cases) HCAP 8.7% (46
cases)
Prina et al. 2015 [50] Prospective study of CAP from Spain
n = 1597
4.5% P. aeruginosa Previous antibiotic use, chronic
respiratory diseases, PO2/FiO2 ratio
< 200
Cillóniz et al. 2016 [11] Prospective study of adult patients
with CAP with definitive etiology
n = 2023
4% P. aeruginosa 1.08% MDR
P. aeruginosa
Male sex, chronic respiratory diseases,
C-reactive protein < 12.35 mg/dL, PSI
IV to V Prior antibiotic treatment risk
factor for MDR P. aeruginosa
Restrepo et al. 2018 [10] Multicenter, point-prevalence study
of CAP patients (22 hospitals in 54
countries) n = 3193
4.2% of all population 11.3% of cases
with defined etiology 2% antibiotic-
resistant P. aeruginosa 1% MDR
P. aeruginosa
Prior pseudomonas infection/
colonization, prior tracheostomy,
bronchiectasis, IRVS, very severe COPD
HCAP healthcare-associated pneumonia, IRVS intensive respiratory or vasopressor support, PSI pneumonia severity index, COPD: chronic obstructive
pulmonary disease
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In recent years, isolates of A. baumannii have been re-
covered from multiple extra-hospital sources, such as
vegetables, water treatment plants, fish and shrimp
farms, apart from its known natural habitat (soil and
humid environments). This broad source of the bacteria
may explain the occurrence of community-acquired
infections [18].
A. baumannii has a natural resistance to desiccation
due to morphological changes that justify its viability for
months. Infections caused by A. baumannii may be very
difficult to treat due to the ability of the bacterium to
evade the host immunity and to form biofilm. Further-
more, A. baumannii has several resistance mechanisms,
including β-lactamases, multidrug efflux pumps,
aminoglycoside-modifying enzymes, permeability defects
and modifications of target sites [19] (Table 1).
The majority of A. baumannii isolates from CAP have
a lower antibiotic resistance than isolates from nosoco-
mial infections. Despite this lower rate of antibiotic re-
sistance, severe CAP is the most frequent clinical
presentation of A. baumannii pneumonia. Caution
should be taken when choosing the empirical antibiotic
therapy. Although use of a ß-lactam plus a macrolide or
a fluoroquinolone is the current international guideline
recommendation for severe CAP [1], these drug combi-
nations do not completely cover A. baumannii, mostly
because of its frequent resistance to ceftriaxone [20].
Several studies have reported isolates of MDR A. bau-
mannii in community-dwelling patients and in
nursing-home patients. Recently, a prospective cohort
study of 651 newly admitted patients in six nursing facil-
ities in the USA reported that 95% of patients were admit-
ted for post-acute care; 57% of patients were colonized
with MDR pathogens at enrollment. Prolonged
hospitalization (> 14 days), functional disability, antibiotic
use, or device use were the main risk factors for
colonization at enrollment. The rate per 1000 patient-days
of acquiring a new resistant Gram-negative bacillus was
13.6%. MDR colonization at discharge for resistant
Gram-negative bacilli was 34% [21].
In a study from west China [22], investigating the anti-
microbial susceptibility of 32 isolates of A. baumannii
causing CAP, the authors reported that 30% of the iso-
lates were resistant to the majority of the antibiotics; the
resistant rates to imipenem and meropenem were 19
and 9%, respectively. An important finding of this study
is that approximately 80% of the patients had had a pre-
vious hospital admission.
An MDR A. baumannii was recently isolated in a pre-
viously healthy patient with CAP from Hong Kong. The
patient was treated with intravenous colistin and oral
monocycline and recovered fully [23]. This case is not
isolated and more and more reports of cases of CAP
caused by MDR A. baumannii are being published.
In conclusion, although A. baumannii is not a fre-
quent cause of CAP, the capacity to rapidly develop re-
sistance mechanisms to antibiotics and the fulminant
clinical presentation (with a mortality rate around 50%)
make this pathogen an important health problem, espe-
cially in tropical and subtropical areas.
Prevalence: What is the prevalence?
During the last 10 years, A. baumannii has been de-
scribed as a rare cause of CAP but with clinical rele-
vance. The great majority of CAP cases caused by A.
baumannii occurs in countries with tropical or
sub-tropical climates. A. baumannii is an emerging
pathogen in the regions of Asia-Pacific, with a higher
prevalence in Hong Kong, Singapore, Taiwan, South
Korea and Australia [24, 25].
CAP cases caused by A. baumannii are very rare in
Europe and USA. A recent USA case report of severe
CAP and review of the literature found that 19 cases of
CAP caused by A. baumannii have been reported in the
USA to date [26].
Unlike nosocomial pneumonia caused by A. bauman-
nii, CAP cases caused by A. baumannii have a seasonal
presentation, with the highest prevalence during the
warm and humid months of the year [25].
A. baumannii risk factors
The clinical presentation of A. baumannii CAP is ful-
minant with acute onset of fever, dyspnea and rapid pro-
gression to respiratory failure and shock. A. baumannii
CAP is associated with a mortality rate ranging from 40
to 60% especially in cases presenting with bacteremia
and shock. The main risk factors related to this infection
are alcoholism, diabetes mellitus and chronic lung
disease [24].
It is known that alcohol abuse impacts on the innate
and adaptive immune response. A study published in
2013 described the impact of alcohol on macrophage-like
cell antimicrobial functions in A. baumannii infections
[27]. The authors demonstrated that alcohol plays an im-
portant role in inhibiting nitric oxide (NO) production
which is essential to eradicate bacteria exposed to macro-
phages after phagocytosis. Alteration of intra- and
extra-cellular NO production promotes microbial survival,
facilitating intracellular replication. Furthermore, macro-
phages exposed to alcohol have lower production of
pro-inflammatory tumor necrosis factor (TNF)-α, inter-
leukin (IL)-1β, and IL-12 and increased levels of IL-6. This
imbalance in the production of cytokines affects the differ-
entiation of naïve T cells into Th1 cells because of low
IL-12 production, and the production of interferon
(IFN)-γ from T and natural killer (NK) cells. Moreover, it
is known that low levels of TNF-α and IL-1β are
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associated with septic shock and the risk of bacterial
infections [27].
A related study recently published by Kamoshida et al.
[28] described for the first time the ability of A. bau-
mannii to inhibit the formation of neutrophil extracellu-
lar traps (NETs), thus suppressing neutrophil adhesion.
It is well known that the main role of NETs is to prevent
microbial dissemination and to eradicate pathogens. The
ability of A. baumannii to escape the immune response
may explain the fulminant clinical presentation of CAP
caused by this pathogen.
An Australian study suggested that microaspiration of
pharyngeal A. baumannii may be responsible for CAP in
alcoholic patients [29]. In this study, 10% of community
residents attending the Emergency Department in the
wet-season (March–April) with non-respiratory diseases,
no episode of previous hospitalization and a history of
alcohol abuse (alcohol intake > 6 standard drinks/day)
had A. baumannii in their throat [29].
The susceptibility to pneumonia in patients with dia-
betes can be ascribed to several factors. Patients with
diabetes have an increased risk of hyperglycemia (which
reduces the mobilization of polymorphonuclear leuko-
cytes, chemotaxis and phagocytic activity), increased risk
of aspiration, impaired immunological defenses, and de-
terioration in lung function and chronic complications,
such as neuropathy [30].
Patients with underlying chronic lung disease, such as
COPD or bronchiectasis, also show reduced innate
defense mechanisms. Generally, these patients are
smokers, passive smokers or ex-smokers and the fre-
quent use of inhaled corticosteroids make them more
vulnerable to infections such as pneumonia [10, 11, 27].
In conclusion, because of its possible fulminating
course, CAP caused by A. baumannii should be sus-
pected in patients with specific risk factors and a severe
presentation of pneumonia. Early recognition and
prompt initiation of broad empirical antibiotic coverage
are mandatory to limit the high mortality related to this
infection.
CAP caused by Klebsiella pneumoniae
The pathogen: What is so special about K. pneumoniae in
CAP?
K. pneumoniae is a Gram-negative capsulate bacterium
responsible for severe pneumonia especially in im-
munocompromised patients. In the last two decades,
there has been an increase in antibiotic resistance in
K. pneumoniae isolates globally. The emergency of
MDR and hypervirulent K. pneumoniae strains has
been reported in immunocompromised patients and
in healthy persons [31].
The main mechanisms of antibiotic resistance in K.
pneumoniae are the expression of extended spectrum
β-lactamases (ESBLs), which confers resistance against
penicillins, cephalosprins and monobactams, and the ex-
pression of carbapenemases, which confers resistance
against all β-lactams including carbapenems (Table 1).
Interestingly, hypervirulent K. pneumoniae strains pro-
duce a hypercapsule, also known as being hypermucovis-
cous. The capsule, a polysaccharide matrix that coats the
cell, is necessary for K. pneumoniae virulence and is ar-
guably the most thoroughly studied virulence factor of
K. pneumoniae [31]. Although antimicrobial resistance
in hypervirulent K. pneumoniae is generally lower than
in non-hypervirulent K. pneumoniae strains, cases with
more resistant strains of hypervirulent K. pneumoniae
have recently been reported [32].
K. pneumoniae has the ability to avoid phagocytosis. A
recent experimental study found that the capsule is dis-
pensable for intracellular Klebsiella survival if bacteria
are not opsonized. K. pneumoniae survives the killing by
macrophages by manipulating phagosome maturation,
which may contribute to Klebsiella pathogenesis [33].
In conclusion, CAP caused by MDR and hypervirulent
K. pneumoniae represents a great challenge in terms of
treatment and management, especially in Asian coun-
tries, where the majority of cases are reported.
Prevalence: What is the prevalence?
A recent 5-year study in a French ICU [34] described 59
infections caused by K. pneumoniae; 26 (44%) of them
were community-onset infections. Interestingly, the au-
thors reported 12 hypervirulent K. pneumoniae strains
in the group of community-onset infections, 6 (50%) of
which were isolated from patients with CAP. The au-
thors observed that hypervirulent K. pneumoniae cases
had higher rates of organ failure compared with
non-hypervirulent cases. However, mortality rates were
similar in the two groups.
In a study performed in Cambodia [35], 2315 patients
with acute lower respiratory infections were enrolled, in-
cluding 587 (25%) whose bacterial etiology could be
assigned. K. pneumoniae was identified in 8% (n = 47) of
the microbiologically-confirmed cases. ESBL-producing
strains were found in 8 (17%) patients. The main risk
factors related to K. pneumoniae infection were female
sex and diabetes mellitus. The overall mortality rate due
to K. pneumoniae infection was 38%.
Approximately 1–7% of cases of CAP are caused by K.
pneumoniae, with 5–36% of these being MDR strains [2,
36]. Interestingly, in Asian countries (Taiwan, Cambodia,
Shanghai) K. pneumoniae is described as a frequent
pathogen causing bacteremia [37, 38]. Although reports
of cases from Europe and USA are generally rare, an in-
creasing incidence from these regions has been regis-
tered in recent years [34, 39].
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K. pneumoniae risk factors
The recognized risk factors for K. pneumoniae CAP are
female sex, diabetes mellitus and alcoholism. MDR K.
pneumoniae can be recognized as a virulent pathogen
causing severe CAP, frequently associated with septic
shock, respiratory failure and bacteremia. Morbidity and
mortality rates are high especially in Asian countries
were the pathogen is reported in younger patients with
no chronic conditions. This pattern may be explained by
the virulence of the strains (especially hypervirulent K.
pneumoniae) and the high rate of antibiotic consump-
tion in these regions [35, 40].
CAP caused by Stenotrophomonas maltophilia
The pathogen: What is so special about S. maltophilia in
CAP?
S. maltophilia is a motile, aerobic, non-fermentative
Gram-negative bacillus with the ability to survive on any
humid surface, form biofilm and colonize humid sur-
faces. It is an emerging opportunistic pathogen with
multidrug resistance, which particularly affects immuno-
compromised patients (i.e., with malignances, post-organ
transplantation) worldwide [41, 42].
S. maltophilia is intrinsically resistant to carbapenems
and frequently carries genetic elements that provide re-
sistance to other β-lactams, fluoroquinolones, aminogly-
cosides and tetracyclines. S. maltophilia has the ability
to acquire genes involved in antibiotic resistance from
other bacterial species. The most relevant mechanisms
of antibiotic resistance include β-lactamase (L1 and L2)
production, multidrug efflux pumps (which confer resist-
ance to macrolides, quinolones, aminoglucosydes, poly-
myxins), antibiotic-modifying enzymes, mutations of
bacterial topoisomerase and gyrase genes and reduction
in outer membrane permeability [42] (Table 1).
Although S. maltophilia has been reported in patients
with cystic fibrosis, it can affect healthy individuals
through contaminated wounds or infected catheters [43,
44]. Transmission of S. maltophilia may occur through
direct contact with contaminated source such as con-
taminated water or medical devices [42].
In conclusion, CAP caused by S. maltophilia is associ-
ated with high mortality rates. Hemorrhagic pneumonia
is one of the most severe forms of S. maltophilia infec-
tion [45]. It is associated with poor outcome despite ap-
propriate antibiotic therapy.
Prevalence: What is the prevalence?
There is limited information on the worldwide preva-
lence of community-acquired S. maltophilia pneumonia.
The majority of data comes from case reports [46]. S.
maltophilia has been reported as an important cause of
CAP in patients with hematologic diseases, with a preva-
lence of bacteremia ranging between 2 and 7%. The
mortality rate is approximately 35% (ranging between 30
and 40%) in this special population.
S. maltophilia risk factors
The majority of patients affected by this pathogen have
previous chronic comorbidities, such as COPD, cystic fi-
brosis, malignancy (especially hematologic diseases), hu-
man immunodeficiency virus (HIV)-infection (acquired
immunodeficiency syndrome [AIDS]) or other immuno-
deficiencies. Patients with prior antimicrobial therapy,
prolonged hospitalization, indwelling catheters, mechan-
ically ventilated and receiving corticosteroids have an in-
creased risk of S. maltophilia CAP [42, 46].
Diagnosis: Is it possible to predict gram-negative
MDR pathogens in CAP?
The reference microbiological diagnostic tools for bac-
teria causing respiratory tract infections remain the
Gram stain and semi-quantitative conventional cultures
from direct respiratory samples. Bacterial identification
is currently based on matrix-assisted latex laser desorp-
tion/ionization time-of-flight mass spectrometry (MAL-
DI-TOF MS) and susceptibility testing. As a
consequence of the time needed for microbiological
diagnosis, many patients initially receive inappropriate
antibiotic treatment, which may increase morbidity and
mortality.
Molecular techniques based on multiplex PCR have
also been developed in recent years in order to simul-
taneously identify and quantify multiple respiratory
pathogens from different types of samples in a single
procedure [47]. However, the main challenge for the
rapid diagnosis of respiratory infections is the early
detection of the antibiotic resistance profile of the
various bacteria. The biggest obstacle in the use of
molecular techniques for detecting resistance is the
discrepancy between genotype and phenotype, the
continuous discovery of new resistance mechanisms
and, as a result, the potential presence of unknown
mechanisms, which may lead to false negative results
using molecular techniques [47].
Recognizing patients at risk of colonization with MDR
Gram-negative bacteria, such as patients with bronchiec-
tasis or COPD (frequently colonized by P. aeruginosa), is
essential, since several studies have reported the
association between previous colonization and risk of
pneumonia [48, 49].
Currently, there is no specific score to predict MDR
Gram-negative pathogens in CAP. However, several scor-
ing systems have been proposed to identify patients with
risk factors for developing CAP caused by MDR patho-
gens. The Aliberti score [2] takes into account different
variables and gives a specific score to each of them:
chronic renal failure (5 points), prior hospitalization (4
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points), nursing home residence (3 points) and other vari-
ables (0.5 points each). CAP patients with an Aliberti
score ≥ 3 points have a reported prevalence of MDR of
38%, whereas CAP patients with an Aliberti score of ≤0.5
have a reported prevalence of MDR of 8%. The PES (P.
aeruginosa, Enterobacteriaceae ESBL-positive, methicillin-
resistant S. aureus [MRSA]) score includes 1 point each
for age 40–65 years and male sex; 2 points each for age >
65 years, previous antibiotic use, chronic respiratory dis-
order, and impaired consciousness; 3 points for chronic
renal failure; and minus 1 point if fever is present initially.
The risk of MDR pathogens is higher with 5 points or
more [50]. Unfortunately, studies validating the Aliberti
and PES score do not include immunocompromised pa-
tients. The ability of these scores to identify risk factors
for CAP by MDR pathogens in this population is still
unclear.
An important study by Shindo et al. [51] investigated
the main risk factors for MDR pathogens in 1413 pa-
tients with CAP. Six risk factors were identified: prior
hospitalization, immunosuppression, previous antibiotic
use, use of gastric acid-suppressive agents, tube feeding
and non-ambulatory status. Unlike the Aliberti and PES
studies, Shindo’s study included immunocompromised
patients. Interestingly, the authors analyzed risk factors
for Gram-positive (MRSA) and Gram-negative patho-
gens separately. The authors observed that the risk of
MDR Gram-negative pathogens did not increase in the
presence of ≥3 risk factors; conversely, for Gram-positive
(MRSA) pathogens, the risk increased in the presence of
≥2 risk factors, especially if one of the risk factors was
specific for MRSA, such as previous colonization or pre-
vious hospitalization.
Therapy: How is it possible to treat these
pathogens?
Since antibiotic treatment for P. aeruginosa is com-
pletely different from standard therapy to cover the most
common pathogens in CAP, current international guide-
lines for severe CAP stratify therapy recommendations
on the basis of P. aeruginosa risk factors [1]. MDR P.
aeruginosa should be covered only in cases that are
strongly suspected because of concurrent risk factors. It
is important to underline that prior antibiotic therapy
has been reported as the only risk factor for MDR P.
aeruginosa in CAP patients [11].
Empirical antibiotic treatment based on the evaluation
of the patient’s risk factors is also of pivotal importance
in the management of A. baumannii CAP.
Because CAP caused by A. baumannii has a fulminant
clinical presentation with a high mortality rate (approxi-
mately 50%), greater attention should be paid in elderly
patients with multi-comorbidities, and patients with al-
cohol abuse, chronic lung disease and prior antibiotic
therapy, especially in Asian countries where this patho-
gen is frequently reported. Early appropriate antimicro-
bial therapy is critical. Recommended empirical
antibiotic therapy for A. baumannii CAP includes
anti-pseudomonal penicillins, aminoglycoside, ciproflox-
acin, and imipenem. Tigecycline, colistin, ceftazidime,
doxycycline, minocycline, piperacillin/tazobactam, tobra-
mycin, rifampin, fosfomycin and levofloxacin are active
against variable percentages of strains. The treatment
should include an association of two or more of these
antibiotics according to the antibiogram of the isolated
pathogen. Moreover some countries, notably Asia [52]
and Australia [53], have implemented specific antibiotic
recommendations in cases of severe CAP in order to
cover pathogens such as A. baumannii.
In CAP caused by K. pneumoniae, depending on the
clinical severity and the risk of infection by a strain with
resistance mechanisms (production of ESBLs, cefaminases
or carbapenemases), a 3rd generation cephalosporin (cefo-
taxime or ceftriaxone) or a fluoroquinolone (ciprofloxacin
or levofloxacin) should be used. Another possibility, in
case of infection by carbapenemase-producing or
carbapenem-resistant strains (due to loss of porin and hy-
perproduction of Amp-C), is the use of associations of
two or three of the following antibiotics: colistin, tigecyc-
line, fosfomycin (if the strain is sensitive), an aminoglyco-
side (amikacin or gentamicin) and meropenem (if the
minimum inhibitory concentration [MIC] = 16mg/L), ad-
ministered in high doses and by continuous perfusion. Hy-
pervirulent strains (serotypes K1 and K2) are usually more
sensitive to antibiotics, but production of K. pneumoniae--
type carbapenemase has also been observed.
For the antibiotic treatment of S. maltophilia pneumo-
nia, trimethoprim-sulfamethoxazole (TMP-SMX) is still
considered the drug of choice despite increasing resist-
ance. It is preferably used in association with another
antibiotic depending on the severity of the pneumonia
and the sensitivity of the pathogen. Other alternative an-
tibiotics include β-lactams (i.e., ceftazidime), fluoroqui-
nolones (i.e., levofloxacin, moxifloxacin), minocycline or
tigecycline. In vitro, the following associations are often
synergistic: cotrimoxazole with colistin, tigecycline,
ceftazidime and rifampicin; colistin with tigecycline, cef-
tazidime and rifampin; ceftazidime with levofloxacin,
moxifloxacin and aztreonam.
Figure 1 proposes an algorithm for the empiric anti-
biotic therapy of CAP in patients with risks factors for
MDR pathogens.
Conclusion
Correct identification of CAP patients suspected of be-
ing infected with MDR Gram-negative pathogens is cru-
cial. Specific risk factors, local ecology and resistance
patterns should always be considered in order to
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determine the adequate empirical antibiotic therapy.
Early hemodynamic and respiratory support is critical in
these patients since the majority of cases of pneumonia
may become fulminant systemic disease with both re-
spiratory failure and multiple organ dysfunction.
The collaboration of a multidisciplinary team (critical
care specialists, pneumologist, infectious disease special-
ists, microbiologists) improves management of the most
severe cases. The role of the microbiology laboratory, in
particular, is of pivotal importance to determine the anti-
microbial susceptibility pattern of the pathogen causing
CAP, so that appropriate antibiotic therapy can be initi-
ated as soon as possible, avoiding excessive use of broad
spectrum antimicrobials, which increase the selection of
resistant pathogens.
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